Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue)
biomarkers will better predict early brain tumor response to treatments and will be more
reliable prognostic markers in patients with malignant brain tumors.
Details
Lead Sponsor:
Marcelo F. Di Carli, MD, FACC
Collaborators:
General Electric Society of Nuclear Medicine and Molecular Imaging